vs
Side-by-side financial comparison of TPG Mortgage Investment Trust, Inc. (MITT) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $20.4M, roughly 1.0× TPG Mortgage Investment Trust, Inc.). TPG Mortgage Investment Trust, Inc. runs the higher net margin — 65.0% vs -84.4%, a 149.4% gap on every dollar of revenue. On growth, TPG Mortgage Investment Trust, Inc. posted the faster year-over-year revenue change (17.7% vs -65.2%). Over the past eight quarters, TPG Mortgage Investment Trust, Inc.'s revenue compounded faster (9.1% CAGR vs 6.4%).
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
MITT vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $20.6M |
| Net Profit | $13.3M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | 67.1% | -106.0% |
| Net Margin | 65.0% | -84.4% |
| Revenue YoY | 17.7% | -65.2% |
| Net Profit YoY | -7.0% | -173.8% |
| EPS (diluted) | $0.27 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | — | ||
| Q3 25 | $19.5M | — | ||
| Q2 25 | $17.8M | — | ||
| Q1 25 | $18.8M | $20.6M | ||
| Q4 24 | $17.4M | $37.4M | ||
| Q3 24 | $14.9M | $19.6M | ||
| Q2 24 | $16.4M | $94.7M | ||
| Q1 24 | $17.2M | $59.1M |
| Q4 25 | $13.3M | — | ||
| Q3 25 | $20.0M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $11.5M | $-17.3M | ||
| Q4 24 | $14.3M | $1.1M | ||
| Q3 24 | $16.6M | $-14.0M | ||
| Q2 24 | $3.9M | $55.0M | ||
| Q1 24 | $20.9M | $23.5M |
| Q4 25 | 67.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 54.6% | -106.0% | ||
| Q4 24 | 76.7% | -15.7% | ||
| Q3 24 | — | -110.7% | ||
| Q2 24 | 18.4% | 56.4% | ||
| Q1 24 | — | 35.7% |
| Q4 25 | 65.0% | — | ||
| Q3 25 | 102.5% | — | ||
| Q2 25 | 22.2% | — | ||
| Q1 25 | 60.9% | -84.4% | ||
| Q4 24 | 82.2% | 3.0% | ||
| Q3 24 | 111.3% | -71.7% | ||
| Q2 24 | 24.0% | 58.1% | ||
| Q1 24 | 121.6% | 39.7% |
| Q4 25 | $0.27 | — | ||
| Q3 25 | $0.47 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $0.21 | $-0.42 | ||
| Q4 24 | $0.30 | $-0.20 | ||
| Q3 24 | $0.40 | $-0.35 | ||
| Q2 24 | $-0.02 | $1.55 | ||
| Q1 24 | $0.55 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.8M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $560.7M | $417.3M |
| Total Assets | $8.7B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.8M | — | ||
| Q3 25 | $59.0M | — | ||
| Q2 25 | $88.7M | — | ||
| Q1 25 | $115.5M | $67.8M | ||
| Q4 24 | $118.7M | $101.2M | ||
| Q3 24 | $102.5M | $78.0M | ||
| Q2 24 | $120.9M | $185.3M | ||
| Q1 24 | $100.3M | $68.4M |
| Q4 25 | $560.7M | — | ||
| Q3 25 | $559.8M | — | ||
| Q2 25 | $536.4M | — | ||
| Q1 25 | $543.9M | $417.3M | ||
| Q4 24 | $543.4M | $428.7M | ||
| Q3 24 | $540.1M | $422.4M | ||
| Q2 24 | $533.5M | $429.9M | ||
| Q1 24 | $539.6M | $269.4M |
| Q4 25 | $8.7B | — | ||
| Q3 25 | $9.0B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $7.3B | $486.5M | ||
| Q4 24 | $6.9B | $526.3M | ||
| Q3 24 | $7.0B | $554.6M | ||
| Q2 24 | $7.1B | $582.0M | ||
| Q1 24 | $6.4B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $59.6M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 4.48× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $59.6M | — | ||
| Q3 25 | $17.4M | — | ||
| Q2 25 | $11.5M | — | ||
| Q1 25 | $12.0M | $-38.5M | ||
| Q4 24 | $55.8M | $-31.6M | ||
| Q3 24 | $14.5M | $-24.3M | ||
| Q2 24 | $13.7M | $39.8M | ||
| Q1 24 | $12.0M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | 4.48× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 3.91× | -27.94× | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 3.50× | 0.72× | ||
| Q1 24 | 0.57× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
